The Value of Pelvic Magnetic Resonance Imaging in Detecting Bone Marrow Infiltration of Lymphoma

Completed

• Conditions: Lymphoma

• Registration Number: NCT03973164
• Lead Sponsor: Guangxi Medical University

Brief Summary

The diagnosis of lymphoma bone marrow infiltration is very important for the staging and treatment mode of lymphoma. Traditional bone marrow cytology and pathology examinations are only performed locally, and missed diagnosis is possible. The study explore the value of multi-parameter pelvic magnetic resonance in detecting bone marrow infiltration with newly diagnosed lymphoma patients . This study also explore the consistency of pelvic magnetic resonance and PET/CT for detection of lymphoma bone marrow infiltration.

Detailed Description

Not available

Study Timeline

• Study Start: 2018-02-02
• Primary Completion: 2019-05-22
• Study Completion: 2019-05-22
• Status Verified: 2019-06
• Study First Submitted: 2019-06-01
• Study First Submitted QC: 2019-06-03
• Last Update Submitted: 2019-06-03
• Study First Posted: 2019-06-04
• Last Update Posted: 2019-06-04

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 142

Inclusion Criteria

• Lymphoma subtypes were diagnosed on the basis of tissue samples obtained by biopsy or surgery according to the criteria outlined in the current World Health Organization (WHO) classification of hematologic and lymphoid malignancies, by are reference pathologist.
• Patients who gave written informed consent were referred for MRI.
• Stable physical medical conditions (patients conscious and comfortable, scheduled for an elective diagnostic imaging).

Exclusion Criteria

• Pregnancy, general contraindications to MRI.

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Agreement Between MRI and Bone marrow cytology, pathology and follow-up at Diagnosis	Within 30 days prior to start of chemotherapy	MRI-positive lesions that cannot be confirmed by bone marrow cytology and pathology will be confirmed by MRI follow-up.

Secondary Outcome Measures

Name	Time	Method
Agreement Between MRI and 18F-FDG PET/CT at Diagnosis	Within 30 days prior to start of chemotherapy	Region based agreement (%; kappa value) of MRI with 18F-FDG PET/CT at diagnosis.

Trial Locations

Locations (1)

Affiliated Tumor Hospital，Guangxi Medical University; 🇨🇳 Nanning, China